Overview

A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis

Status:
Completed

Trial end date:
2018-08-01

Target enrollment:

Participant gender:

Summary

This is a study to evaluate the efficacy and safety of different doses of bimekizumab in subjects with active Ankylosing Spondylitis (AS).

Phase:

Phase 2

Details

Lead Sponsor:

UCB Biopharma S.P.R.L.